Skip to main content

Advertisement

SpringerLink
Log in

Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma

  • Research Article
  • Published:
Tumor Biology

Abstract

The purpose of the present study was to detect the expression levels of circulating miR-148a in the peripheral blood of osteosarcoma patients and to further investigate the clinicopathological, diagnostic, and prognostic value of miR-148a. Eighty-nine patients with initially diagnosed osteosarcoma who successfully underwent surgical resection were enrolled in this prospective study. The expression levels of circulating miR-148a were detected by real-time quantitative RT-PCR. All statistical analyses were performed with SPSS 18.0 statistical software to determine the potential values of circulating miR-148a on the clinicopathological factors, diagnosis, and prognosis. The expression levels of circulating miR-148a in osteosarcoma patients were significantly higher than that in the healthy controls (P < 0.001), and miR-148a was capable of distinguishing osteosarcoma patients from healthy controls effectively (AUC = 0.783). In addition, miR-148a expression was significantly associated with tumor size (P = 0.049) and distant metastasis (P = 0.004). Univariate survival analysis demonstrated that patients with miR-148a high expression had significantly poor overall survival (P < 0.001) and disease-specific survival (P < 0.001) after 5 years’ operation. Multivariate survival analysis confirmed that miR-148a high expression was an independent predictor for unfavorable overall survival (P = 0.003) and disease-specific survival (P = 0.008), respectively. Our findings demonstrated that detection of circulating miR-148a expression in the peripheral blood have clinical potentials as an indicator of progressive phenotype, a novel diagnostic biomarker and a promising predictor to identify individuals with poor prognosis for osteosarcoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–34.

    Article  CAS  Google Scholar 

  2. Mangat KS, Jeys LM, Carter SR. Latest developments in limb-salvage surgery in osteosarcoma. Expert Rev Anticancer Ther. 2011;11:205–15.

    Article  Google Scholar 

  3. Tan P, Zou C, Yong B, et al. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun. 2012;419:801–8.

    Article  CAS  Google Scholar 

  4. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21:229–35.

    CAS  PubMed  Google Scholar 

  5. Jaffe N. Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication. Cancer Treat Res. 2009;152:219–37.

    Article  Google Scholar 

  6. Baumhoer D, Smida J, Zillmer S, et al. Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol. 2012;25:522–8.

    Article  CAS  Google Scholar 

  7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  Google Scholar 

  8. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.

    Article  CAS  Google Scholar 

  9. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 2010;70:6401–6.

    Article  CAS  Google Scholar 

  10. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 2007;7:297–304.

    Article  CAS  Google Scholar 

  11. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature. 2005;435:745–6.

    Article  CAS  Google Scholar 

  12. Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotech. 2010;2:161–79.

    CAS  Google Scholar 

  13. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  CAS  Google Scholar 

  14. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.

    Article  CAS  Google Scholar 

  15. Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci. 2012;19:90.

    Article  CAS  Google Scholar 

  16. Croce C. Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 2012;18:213–4.

    Article  Google Scholar 

  17. Corsini LR, Bronte G, Terrasi M, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16:S103–9.

    Article  CAS  Google Scholar 

  18. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14:1170–9.

    Article  Google Scholar 

  19. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429–38.

    Article  Google Scholar 

  20. Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011;18:1702–10.

    Article  CAS  Google Scholar 

  21. Takahashi M, Cuatrecasas M, Balaguer F, et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS ONE. 2012;7:e46684.

    Article  CAS  Google Scholar 

  22. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.

    Article  Google Scholar 

  23. Fujita Y, Kojima K, Ohhashi R, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285:19076–84.

    Article  CAS  Google Scholar 

  24. Murata T, Takayama K, Katayama S, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 2010;13:356–61.

    Article  CAS  Google Scholar 

  25. Baumhoer D, Elsner M, Smida J, et al. CRIP1 expression is correlated with a favorable outcome and less metastasis in osteosarcoma patients. Oncotarget. 2011;2:970–5.

    Article  Google Scholar 

  26. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5:e13735.

    Article  Google Scholar 

  27. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn. 2011;11:259–75.

    Article  CAS  Google Scholar 

  28. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12:1117–25.

    PubMed  Google Scholar 

  29. Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42.

    Article  CAS  Google Scholar 

  30. Madhavan D, Zucknick M, Wallwiener M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012;18:5972–82.

    Article  CAS  Google Scholar 

  31. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–33.

    Article  CAS  Google Scholar 

  32. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the grant from the Scientific Research Project of the Second Hospital of Shandong University (Y2013010054).

The authors were grateful toYuan Zhang (Department of Evidence-based medicine) for his technical guide and data analysis from the Second Hospital of Shandong University, Shandong University, China.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Orthopedics, the Second Hospital of Shandong University, Shandong University, Bei yuan da jie 247, 250033, Jinan, China

    Wanli Ma, Peng Chen, Peng Ren & Mingzhi Gong

  2. Department of Clinical Laboratory, the Second Hospital of Shandong University, Shandong University, Bei yuan da jie 247, 250033, Jinan, China

    Xuhua Zhang

  3. Department of Gastrointestinal Surgery, Cancer Prevention and Research Institute of Shandong Province, Ji yan road 440, 250355, Jinan, China

    Jie Chai

Authors
  1. Wanli Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Chai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peng Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mingzhi Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mingzhi Gong.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, W., Zhang, X., Chai, J. et al. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumor Biol. 35, 12467–12472 (2014). https://doi.org/10.1007/s13277-014-2565-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2565-x

Keywords

Search

Navigation